Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo...

Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...

David Thompson, PhD to Lead Azure Biotech as President GALES FERRY, CT--(Marketwired - March 08, 2016) - Azure Biotech, Inc. a private biotechnology company developing novel formulations of lasofoxifene announced today that David Thompson, PhD will...

Azure Biotech Announces Hiring of Ralph Makar as CEO NEW YORK, NY--(Marketwired - December 17, 2013) - Azure Biotech Inc. today announced that it has hired Ralph Makar as Chief Executive Officer (CEO), effective...